AAAAAA
Results:
1-17
|
Results: 17
Authors:
Wagenaar, HC
Pecorelli, S
Mangioni, C
van der Burg, MEL
Rotmensz, N
Anastasopoulou, A
Zola, P
Veenhof, CHN
Lacave, AJ
Neijt, JP
van Oosterom, AT
Einhorn, N
Vermorken, JB
Citation: Hc. Wagenaar et al., Phase II study of mitomycin-C and cisplatin in disseminated, squamous cellcarcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study, EUR J CANC, 37(13), 2001, pp. 1624-1628
Authors:
Duffaud, F
van der Burg, MEL
Namer, M
Vergote, I
Willemse, PHB
Huinink, WT
Guastalla, JP
Nooij, MA
Kerbrat, P
Piccart, M
Tumolo, S
Favalli, G
van der Vange, N
Lacave, AJ
Wils, J
Splinter, TAW
Einhorn, N
Roozendaal, KJ
Rosso, R
Vermorken, JB
Citation: F. Duffaud et al., D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study, ANTI-CANC D, 12(2), 2001, pp. 159-162
Authors:
Vermorken, JB
Zanetta, G
Oliveira, CFD
van der Burg, MEL
Lacave, AJ
Teodorovic, I
Boes, GH
Colombo, N
Citation: Jb. Vermorken et al., Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma ofthe uterine cervix: An EORTC Gynecological Cancer Cooperative Group study, ANN ONCOL, 12(7), 2001, pp. 967-974
Authors:
Schuyer, M
van der Burg, MEL
Henzen-Logmans, SC
Fieret, JH
Klijn, JGM
Look, MP
Foekens, JA
Stoter, G
Berns, EMJJ
Citation: M. Schuyer et al., Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2, BR J CANC, 85(9), 2001, pp. 1359-1367
Authors:
Gelderblom, H
Sparreboom, A
de Jonge, MJA
Loos, WJ
Wilms, E
Mantel, MA
Hennis, B
Camlett, I
Verweij, J
van der Burg, MEL
Citation: H. Gelderblom et al., Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer, BR J CANC, 85(8), 2001, pp. 1124-1129
Authors:
van Zuylen, L
Sparreboom, A
van der Gaast, A
van der Burg, MEL
van Beurden, V
Bol, CJ
Woestenborghs, R
Palmer, PA
Verweij, J
Citation: L. Van Zuylen et al., The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel, CLIN CANC R, 6(4), 2000, pp. 1365-1371
Authors:
Gelderblom, AJ
Loos, WJ
de Jonge, MJA
Sparreboom, A
Planting, AST
van der Burg, MEL
Brouwer, E
Verheij, C
Ouwens, L
Hearn, S
Verweij, J
Citation: Aj. Gelderblom et al., Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin, ANN ONCOL, 11(9), 2000, pp. 1205-1207
Authors:
de Jonge, MJA
Loos, WJ
Gelderblom, H
Planting, AST
van der Burg, MEL
Sparreboom, A
Brouwer, E
van Beurden, V
Mantel, MA
Doyle, E
Hearn, S
Ross, G
Verweij, J
Citation: Mja. De Jonge et al., Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects, J CL ONCOL, 18(10), 2000, pp. 2104-2115
Authors:
de Jonge, MJA
Sparreboom, A
Planting, AST
van der Burg, MEL
de Boer-Dennert, MM
ter Steeg, J
Jacques, C
Verweij, J
Citation: Mja. De Jonge et al., Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors, J CL ONCOL, 18(1), 2000, pp. 187-194
Authors:
de Jonge, MJA
Verweij, J
Planting, AST
van der Burg, MEL
Stoter, G
de Boer-Dennert, MM
de Bruijn, P
Brouwer, E
Vernillet, L
Sparreboom, A
Citation: Mja. De Jonge et al., Drug-administration sequence does not change pharmacodynamics and kineticsof irinotecan and cisplatin, CLIN CANC R, 5(8), 1999, pp. 2012-2017
Authors:
Gerrits, CJH
Schellens, JHM
Burris, H
Eckardt, JR
Planting, AST
van der Burg, MEL
Rodriguez, GI
Loos, WJ
van Beurden, V
Hudson, I
Von Hoff, DD
Verweij, J
Citation: Cjh. Gerrits et al., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin), CLIN CANC R, 5(1), 1999, pp. 69-75
Authors:
Planting, AST
Schellens, JHM
van der Burg, MEL
de Boer-Dennert, M
Winograd, B
Stoter, G
Verweij, J
Citation: Ast. Planting et al., Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors, ANTI-CANC D, 10(9), 1999, pp. 821-827
Authors:
Sparreboom, A
Planting, AST
Jewell, RC
van der Burg, MEL
van der Gaast, A
de Bruijn, P
Loos, WJ
Nooter, K
Chandler, LH
Paul, EM
Wissel, PS
Verweij, J
Citation: A. Sparreboom et al., Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein, ANTI-CANC D, 10(8), 1999, pp. 719-728
Authors:
de Jonge, MJA
Punt, CJA
Gelderblom, AH
Loos, WJ
van Beurden, V
Planting, AST
van der Burg, MEL
van Maanen, LWGM
Dallaire, BK
Verweij, J
Wagener, T
Sparreboom, A
Citation: Mja. De Jonge et al., Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors, J CL ONCOL, 17(7), 1999, pp. 2219-2226
Authors:
Schuyer, M
Henzen-Logmans, SC
van der Burg, MEL
Fieret, JH
Derksen, C
Look, MP
Meijer-van Gelder, ME
Klijn, JGM
Foekens, JA
Berns, EMJJ
Citation: M. Schuyer et al., Genetic alterations in ovarian borderline tumours and ovarian carcinomas, EUR J OB GY, 82(2), 1999, pp. 147-150
Authors:
Vermorken, JB
Huinink, WWT
Kobierska, A
van der Burg, MEL
Forni, M
Piccart, MJ
van der Putten, E
Citation: Jb. Vermorken et al., Phase I study of high-dose epirubicin in platinum-pretreated patients withovarian carcinoma, ONCOL-BASEL, 57(1), 1999, pp. 10-16
Authors:
de Wit, R
van der Zee, J
van der Burg, MEL
Kruit, WH
Logmans, A
van Rhoon, GC
Verweij, J
Citation: R. De Wit et al., A phase I II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix, BR J CANC, 80(9), 1999, pp. 1387-1391
Risultati:
1-17
|